The Wall Street Journal examines Fred Hassan's go-it-slow approach in turning around Schering-Plough. The CEO has cut dividends to keep the money flowing to R&D and his revamped the company's approach to drug sales. Sales are up, but Hassan is blunt in acknowledging the company's lack of late-stage drug candidates. The quick remedy would be a biotech buyout or a raft of licensing deals, but Hassan says he wants to take his time.
- here's the article on Hassan from The Wall Street Journal (sub. req.)